Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report.

IF 2.8 Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI:10.7573/dic.2025-4-7

Valentina Tuninetti, Roberta Danese, Amedeo Calvo, Marco Bellero, Lavinia Bianco, Valentina Ariu, Maria Grazia Ruo Redda, Paola Campisi, Alessandra Bianco, Giovanni De Rosa, Massimo Petracchini, Giorgio Valabrega

{"title":"Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report.","authors":"Valentina Tuninetti, Roberta Danese, Amedeo Calvo, Marco Bellero, Lavinia Bianco, Valentina Ariu, Maria Grazia Ruo Redda, Paola Campisi, Alessandra Bianco, Giovanni De Rosa, Massimo Petracchini, Giorgio Valabrega","doi":"10.7573/dic.2025-4-7","DOIUrl":null,"url":null,"abstract":"Until recently, treatment options for patients with recurrent or metastatic endometrial cancer (EC) were limited. First-line treatment is usually based on carboplatin and paclitaxel and there was no standard second-line therapy following platinum failure. However, the introduction of immunotherapy has expanded both first-line and later-line options for EC and made determination of mismatch repair status essential. We describe the case of a 56-year-old woman with deficient mismatch repair/microsatellite instability EC who did not respond to first-line treatment with carboplatin and paclitaxel but had a high response to subsequent immunotherapy with dostarlimab. There was initial pseudoprogression of one target lesion but marked improvement in quality of life. This article is part of the New treatment options for advanced endometrial carcinoma Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221137/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2025-4-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Until recently, treatment options for patients with recurrent or metastatic endometrial cancer (EC) were limited. First-line treatment is usually based on carboplatin and paclitaxel and there was no standard second-line therapy following platinum failure. However, the introduction of immunotherapy has expanded both first-line and later-line options for EC and made determination of mismatch repair status essential. We describe the case of a 56-year-old woman with deficient mismatch repair/microsatellite instability EC who did not respond to first-line treatment with carboplatin and paclitaxel but had a high response to subsequent immunotherapy with dostarlimab. There was initial pseudoprogression of one target lesion but marked improvement in quality of life. This article is part of the New treatment options for advanced endometrial carcinoma Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.

查看原文本刊更多论文

免疫疗法治疗晚期子宫内膜癌患者的假进展和生活质量的改善：一例报告。

直到最近，复发或转移性子宫内膜癌（EC）患者的治疗选择是有限的。一线治疗通常基于卡铂和紫杉醇，在铂治疗失败后没有标准的二线治疗。然而，免疫疗法的引入扩大了EC的一线和后期治疗选择，并使错配修复状态的测定变得至关重要。我们描述了一名56岁的女性，患有缺陷错配修复/微卫星不稳定性EC，她对卡铂和紫杉醇的一线治疗没有反应，但对随后的多斯塔利单抗免疫治疗有很高的反应。最初有一个目标病变的假进展，但生活质量明显改善。这篇文章是晚期子宫内膜癌新治疗方案的一部分特刊：https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.